Search
Almonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigational[A231864] Almonertinib was also approved by the EMA on February 20, 2026.[L56068] … [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersSynonyms: 2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-, N-[5-[[4-(1-Cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-2-propenamideVandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalOn April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. … Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamineDiloxanide
go.drugbank.com/drugs/DB08792ExperimentalAlthough it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990.
Categories: Heterocyclic Compounds, 1-RingBMS-214662
go.drugbank.com/drugs/DB12234Investigationaltreatment of Childhood Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, and Adult Acute Promyelocytic Leukemia (M3
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingGlenvastatin
go.drugbank.com/drugs/DB21374ExperimentalGlenvastatin is a small molecule drug. The usage of the INN stem '-vastatin' in the name indicates that Glenvastatin is a antihyperlipidaemic substance, HMG COA reductase inhibitor. … Glenvastatin has a monoisotopic molecular weight of 431.19 Da.
Categories: Heterocyclic Compounds, 1-RingTA-CIN
go.drugbank.com/drugs/DB05809InvestigationalTA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.
Probucol
go.drugbank.com/drugs/DB01599ApprovedInvestigationalWithdrawnA drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
Categories: Compounds used in a research, industrial, or household settingSynonyms: Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptoleLyme disease vaccine (recombinant OspA)
go.drugbank.com/drugs/DB00045ApprovedWithdrawnLipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant. … Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli.
Synonyms: Lipoprotein outer surface a borrelia burgdorferi antigenAvacincaptad pegol
go.drugbank.com/drugs/DB15165ApprovedInvestigational[L47696] AMD is the leading cause of vision loss in developed countries for people over 50 years old, with a global estimate of 170 million individuals affected. … This approval is based on the positive results obtained from 2 phase 3 clinical trials GATHER1 and GATHER2.[L47701]
Pirbuterol
go.drugbank.com/drugs/DB01291ApprovedWithdrawnin a concentration between 10-50%. … Pirbuterol is a beta-2 adrenergic bronchodilator.
Categories: Adrenergic beta-2 Receptor Agonists, Selective Beta 2-adrenergic Agonists